Efficacy and Safety of Ciclesonide (CIC) administered twice daily in pediatric patients with asthma.

Exclusion Criteria

• - Nocturnal awakenings for asthma which require treatment with albuterol/salbutamol for 4 or more nights out of the last 7 days of the screening period;
• - Use of more than 8 puffs/day of albuterol/salbutamol on 3 or more consecutive days within the last 7
• - Upper or lower respiratory tract infection within 4 weeks prior to screening and during screening period;
• - History of life-threatening asthma, including a history of significant hypercarbia (pCO2 >45 mmHg), prior intubation, respiratory arrest, or seizures as a result of an exacerbation of asthma;
• - More than 3 in-patient hospitalization or emergency care visits due to asthma exacerbations in the year prior to screening;
• - Use of injectable or oral corticosteroids within one month prior to screening, or more than 3 bursts) within 6 months prior to screening;